| Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial | |
| Lorenzatti, Alberto J.; Eliaschewitz, Freddy G.; Chen, Yundai; Fialkow, Jonathan; Lu, Juming; Baass, Alexis; Monsalvo, Maria Laura; Hsu, Hui-Chun; Somaratne, Ransi; Ge, Junbo | |
| 刊名 | CLINICAL CARDIOLOGY
 |
| 2018 | |
| 卷号 | 41期号:9 |
| 关键词 | diabetes diabetic dyslipidemia dyslipidemia hypercholesterolemia monoclonal antibody PCSK9 PCSK9 inhibitor |
| ISSN号 | 0160-9289 |
| URL标识 | 查看原文 |
| 语种 | 英语 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/3606754 |
| 专题 | 复旦大学上海医学院 |
| 推荐引用方式 GB/T 7714 | Lorenzatti, Alberto J.,Eliaschewitz, Freddy G.,Chen, Yundai,et al. Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial[J]. CLINICAL CARDIOLOGY,2018,41(9). |
| APA | Lorenzatti, Alberto J..,Eliaschewitz, Freddy G..,Chen, Yundai.,Fialkow, Jonathan.,Lu, Juming.,...&Ge, Junbo.(2018).Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial.CLINICAL CARDIOLOGY,41(9). |
| MLA | Lorenzatti, Alberto J.,et al."Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: The BERSON clinical trial".CLINICAL CARDIOLOGY 41.9(2018). |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论